5 Reasons 2020 Will Be a Big Year for Ionis Pharmaceuticals
Investing in biotech stocks can seem like a speculative gamble on binary outcomes, sort of like buying lottery tickets. Fortunately, there are some mid-cap biotechs actually making a profit and that have development pipelines stocked with drug candidates that could produce big winners, giving patient investors the opportunity for gains while riding out the occasional disappointment.
One such stock is Ionis Pharmaceuticals (NASDAQ: IONS). The company is pioneering an approach called RNA antisense, which can be used to block the production of disease-causing proteins. It's taken the company years to perfect the technology and to solve the problem of getting the drug to the targeted tissues in sufficient concentration to be therapeutic without causing side effects. But now, the company is over that hurdle and is rapidly building a portfolio of drugs to treat a wide range of diseases.
The performance of Ionis' stock was underwhelming in 2019, mostly because investors were concerned about future sales of the company's first big drug success. But here are five reasons why 2020 could be different.
Source Fool.com
